Originally published as JCO Early Release 10.1200/JCO.2007.15.2546 on April 21 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by San-Miguel, J. Articles by Anderson, K. C. Search for Related Content PubMed PubMed Citation Articles by San-Miguel, J. Articles by Anderson, K. C. Social Bookmarking                            What's this?

Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents

Jesús San-Miguel, Jean-Luc Harousseau, Douglas Joshua, Kenneth C. Anderson

From the Servicio de Hematología, Hospital Universitario de Salamanca (Centro de Investigación del Cáncer–Instituto de Biología Molecular del Centro del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas) Salamanca, Spain; University Hospital Nantes, Nantes, France; Institute of Hematology, Royal Prince Alfred Hospital, Sidney, Australia; and the Dana-Farber Cancer Institute, Boston, MA

Corresponding author: Jesús San-Miguel, MD, PhD, Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58, 37007 Salamanca, Spain; e-mail: sanmigiz{at}usal.es

Progress in the understanding of multiple myeloma (MM) cell biology has led to the identification of new relevant prognostic factors and subsequently different risk groups. This concept, together with the recent discovery of new drugs with novel mechanisms of action, will probably lead to individualized treatment according to the different patients’ characteristics. In this review, we focus on current available agents already approved for MM, and discuss individualized treatment approaches for both transplantation candidates (subdivided into standard and high-risk patients) and elderly patients. Future progress in MM will be based on using science to inform the design of the optimal combined treatments, and high throughput assays that can assess the ability of combination therapies to induce death of MM cells, both alone and in the bone marrow microenvironment.

published online ahead of print at www.jco.org on April 21, 2008.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-L. Harousseau and P. Moreau Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma N. Engl. J. Med., June 18, 2009; 360(25): 2645 - 2654. [Full Text] [PDF]

				A. L. Shaffer, N.C. T. Emre, P. B. Romesser, and L. M. Staudt IRF4: Immunity. Malignancy! Therapy? Clin. Cancer Res., May 1, 2009; 15(9): 2954 - 2961. [Abstract] [Full Text] [PDF]

				B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF]

				A. Badros, E. Terpos, E. Katodritou, O. Goloubeva, E. Kastritis, E. Verrou, K. Zervas, M. R. Baer, T. Meiller, and M. A. Dimopoulos Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma J. Clin. Oncol., December 20, 2008; 26(36): 5904 - 5909. [Abstract] [Full Text] [PDF]

				B. G.M. Durie Treatment of Myeloma -- Are We Making Progress? N. Engl. J. Med., August 28, 2008; 359(9): 964 - 966. [Full Text] [PDF]